Trademark: 97364220
Status Date
Thursday, June 22, 2023
Filing Date
Thursday, April 14, 2022
Published for Opposition
Tuesday, November 22, 2022
Abandoned Date
Wednesday, June 21, 2023
5 Nutraceuticals, namely, epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; nutraceuticals, namely, epigenetic drugs targeting arginine methylation in cancer; pharmaceutical preparations in the nature of inhibitors of arginine methylation for the treatment of cancer; pharmaceutical preparations in the nature of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; cancer treatment vaccines; therapeutic vaccines for treating cancer; cancer therapy subsection vaccines; pharmaceutical compounds for the treatment, diagnosis, detection and prevention of cancer; pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer
42 Research and development services in the pharmaceutical and biotechnology fields; medical research and development services in the pharmaceutical and biotechnology fields; scientific research and development services; pharmaceutical research and development services; research and development in the field of epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of epigenetic drugs targeting arginine methylation in cancer; research and development in the field of inhibitors of arginine methylation for the treatment of cancer; research and development in the field of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; research and development in the field of cancer treatment vaccines, therapeutic vaccines for treating cancer and cancer therapy subsection vaccines; research and development in the field of compounds for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer; consultancy, advisory and information services relating to and connected with research and development in the pharmaceutical and biotechnology fields, research and development in the field of epigenetic drugs, and research and development in the field of cancer treatment, diagnosis, detection, and prevention
Jun 22, 2023
Abandonment Notice E-Mailed - After Publication
Jun 22, 2023
Abandonment - After Publication
Jun 21, 2023
Teas Express Abandonment Received
May 12, 2023
Assigned To Examiner
Jan 17, 2023
Noa E-Mailed - Sou Required From Applicant
Nov 22, 2022
Official Gazette Publication Confirmation E-Mailed
Nov 22, 2022
Published For Opposition
Nov 2, 2022
Notification Of Notice Of Publication E-Mailed
Oct 17, 2022
Approved For Pub - Principal Register
Oct 7, 2022
Examiner's Amendment Entered
Oct 7, 2022
Notification Of Examiners Amendment E-Mailed
Oct 7, 2022
Examiners Amendment E-Mailed
Oct 7, 2022
Examiners Amendment -Written
Sep 26, 2022
Examiner's Amendment Entered
Sep 26, 2022
Notification Of Examiners Amendment E-Mailed
Sep 26, 2022
Examiners Amendment E-Mailed
Sep 26, 2022
Examiners Amendment -Written
Sep 21, 2022
Assigned To Examiner
Jun 8, 2022
Teas Change Of Correspondence Received
Jun 8, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 8, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Apr 20, 2022
New Application Office Supplied Data Entered
Apr 18, 2022
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
